stronger warnings to avoid mycophenolate (CellCept, Myfortic) during pregnancy
Please see updated information from the FDA
You'll see stronger warnings to avoid mycophenolate (CellCept, Myfortic) during pregnancy.
This is due to new evidence of a higher risk of miscarriage and birth defects in women taking mycophenolate to prevent transplant rejection.
Get concise, unbiased advice for effective drug therapy, plus CE/CME
Prescriber's Letter includes:
- 12 issues every year, with brief articles about new meds and guidelines
- 48+ CE courses, including the popular CE-in-the-Letter
- Quick reference drug comparison charts
- Access to the entire archive
Already a subscriber? Log in
Volume pricing available. Get a quote